Long non-coding RNAs: key regulators of liver and kidney fibrogenesis

키워드

참고문헌 (97)

1. Chen Y, "Aging reprograms the hematopoietic-vascular niche to impede regeneration and promote fibrosis", Cell Metab, 33, pp.395~410 (2021)
2. Davidson MD, "Engineered biomaterial platforms to study fibrosis", Adv Healthc Mater, 9, pp.e1901682~ (2020)
3. Zhao X, "Targeting metabolic dysregulation for fibrosis therapy", Nat Rev Drug Discov, 19, pp.57~75 (2020)
4. 이재호, "Function of gaseous hydrogen sulfide in liver fibrosis", BMB Reports, 55(10), pp.481~487 (2022), 생화학분자생물학회
5. Sul A Lee, "Therapeutic application of extracellular vesicles for various kidney diseases: a brief review", BMB Reports, 55(1), pp.3~10 (2022), 생화학분자생물학회
6. Qin XJ, "Exosomes as mediators and biomarkers in fibrosis", Biomark Med, 14, pp.697~712 (2020)
7. Brigstock DR, "Extracellular vesicles in organ fibrosis : mechanisms, therapies, and diagnostics", Cells, 10, pp.1596~ (2021)
8. Barinotti A, "Serum Biomarkers of renal fibrosis : a systematic review", Int J Mol Sci, 23, pp.14139~ (2022)
9. Caligiuri A, "Cellular and molecular mechanisms underlying liver fibrosis regression", Cells, 10, pp.2759~ (2021)
10. Ulukan B, "Advances in the epigenetics of fibroblast biology and fibrotic diseases", Curr Opin Pharmacol, 49, pp.102~109 (2019)
11. Xue T, "Epigenetic regulation in fibrosis progress", Pharmacol Res, 173, pp.105910~ (2021)
12. Yang Z, "TGF-β1", Smad3 upregulates UCA1 to promote liver fibrosis through DKK1and miR18a, 2022, pp.100, 1465~1478
13. Xia W, "Long non-coding RNA : an emerging contributor and potential therapeutic target in renal fibrosis", Front Genet, 12, pp.682904~ (2021)
14. Chen T, "LncRNA airn maintains LSEC differentiation to alleviate liver fibrosis via the KLF2-eNOS-sGC pathway", BMC Med, 20, pp.335~ (2022)
15. Ye Y, "Role of long non-coding RNA-adducin 3 antisense RNA1 in liver fibrosis of biliary atresia", Bioengineered, 13, pp.6222~6230 (2022)
16. Navarro-Corcuera A, "Long non-coding RNA ACTA2-AS1 promotes ductular reaction by interacting with the p300", ELK1 complex, 2022, pp.76, 921~933
17. Zhang Y, "lncRNA TUG1 regulates hyperuricemia-induced renal fibrosis in a rat model", Acta Biochim Biophys Sin(Shanghai), 54, pp.1365~1375 (2022)
18. Luo Q, "Long noncoding RNA MEG3-205", Let-7a, Kidney Dis(Basel), pp.2022, 8[DOI]
19. Cao L, "The function of long non-coding RNA in non-alcoholic fatty liver disease", Clin Res Hepatol Gastroenterol, 47, pp.102095~ (2023)
20. Xiang Z, "Retard or exacerbate : role of long non-coding RNA growth arrest-specific 5 in the fibrosis", Cytokine Growth Factor Rev, 67, pp.89~104 (2022)
21. Sen I, "Long noncoding RNA lnc-CHAF1B-3 as a new player in fibrosis", Mol Ther Nucleic Acids, 31, pp.566~567 (2023)
22. Statello L, "Gene regulation by long non-coding RNAs and its biological functions", Nat Rev Mol Cell Biol, 22, pp.96~118 (2021)
23. Uthaya Kumar DB, "Long non-coding RNAs in immune regulation and their potential as therapeutic targets", Int Immunopharmacol, 81, pp.106279~ (2020)
24. Lin J, "Emerging roles of long non-coding RNAs in renal fibrosis", Life(Basel), 10, pp.131~ (2020)
25. Xiao X, "LncRNA ENST 00000453774. 1 contributes to oxidative stress defense dependent on autophagy mediation to reduce extracellular matrix and alleviate renal fibrosis", J Cell Physiol, 234, pp.9130~9143 (2019)
26. Wang Z, "The roles and mechanisms of lncRNAs in liver fibrosis", Front Pharmacol, 12, pp.779606~ (2021)
27. Peng H, "The roles of lncRNA in hepatic fibrosis", Cell Biosci, 8, pp.63~ (2018)
28. Israelsen M, "Rifaximinalpha for liver fibrosis in patients with alcohol-related liver disease(GALA-RIF) : a randomised, double-blind, placebocontrolled, phase 2 trial", Lancet Gastroenterol Hepatol, 8, pp.523~532 (2023)
29. Lv H, "Liver fibrosis is closely related to metabolic factors in metabolic associated fatty liver disease with hepatitis B virus infection", Sci Rep, 13, pp.1388~ (2023)
30. Peiseler M, "Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease-novel insights into cellular communication circuits", J Hepatol, 77, pp.1136~1160 (2022)
31. Xiong YT, "Autoimmunity associates with severity of illness in elderly patients with drug-induced liver injury", Front Pharmacol, 14, pp.1071709~ (2023)
32. Omar H, "Evolution of liver fibrosis after interferon-based anti-hepatitis C virus therapy failure in 3, 049 chronic hepatitis C patients without cirrhosis", Arab J Gastroenterol, 24, pp.65~72 (2023)
33. Zhao M, "Targeting fibrosis, mechanisms and cilinical trials", Signal Transduct Target Ther, 7, pp.206~ (2022)
34. Denicolo S, "Assessment of fibrinogen-like 2(FGL2)in Human chronic kidney disease through transcriptomics data analysis", Biomolecules, 13, pp.89~ (2022)
35. Juin SK, "Glucosidase inhibitor, nimbidiol ameliorates renal fibrosis and dysfunction in type-1 diabetes", Sci Rep, 12, pp.21707~ (2022)
36. Liu Y, "MicroRNA-122-5p promotes renal fibrosis and injury in spontaneously hypertensive rats by targeting FOXO3", Exp Cell Res, 411, pp.113017~ (2022)
37. Lv K, "Extracellular vesicles as advanced therapeutics for the resolution of organ fibrosis : current progress and future perspectives", Front Immunol, 13, pp.1042983~ (2022)
38. Shen F, "Histone acetylation and modifiers in renal fibrosis", Front Pharmacol, 13, pp.760308~ (2022)
39. Mutsaers HA, "Editorial : organ fibrosis : triggers, pathways, and cellular plasticity", Front Med(Lausanne), 3, pp.55~ (2016)
40. Yoshimura H, "Expression and role of long non-coding RNA H19 in carcinogenesis", FBL, 23, pp.614~625 (2018)
41. Song Y, "H19 promotes cholestatic liver fibrosis by preventing ZEB1-mediated inhibition of epithelial cell adhesion molecule", Hepatology, 66, pp.1183~1196 (2017)
42. Zhang K, "The liver-enriched lnc-LFAR1 promotes liver fibrosis by activating TGFbeta and Notch pathways", Nat Commun, 8, pp.144~ (2017)
43. Dong BS, "Huangqi decoction, a compound Chinese herbal medicine, inhibits the proliferation and activation of hepatic stellate cells by regulating the long noncoding RNA-C18orf26-1", microRNA-663a, J Integr Med, pp.2023, 21[DOI]
44. Li Y, "Long non‑coding RNA MBI‑52 inhibits the development of liver fibrosis by regulating the microRNA‑466g", SMAD4 signaling pathway, 2022, pp.25, 33~
45. Zhang K, "SCARNA10, a nuclear-retained long non-coding RNA, promotes liver fibrosis and serves as a potential biomarker", Theranostics, 9, pp.3622~3638 (2019)
46. Zhao D, "LncRNA SNHG7 functions as an oncogene in cervical cancer by sponging miR-485-5p to modulate JUND expression", Onco Targets Ther, 13, pp.1677~1689 (2020)
47. Shan Y, "LncRNA SNHG7 sponges miR-216b to promote proliferation and liver metastasis of colorectal cancer through upregulating GALNT1", Cell Death Dis, 9, pp.722~ (2018)
48. Bai Z, "Long non-coding RNA SNGH7 Is activated by SP1 and exerts oncogenic properties by interacting with EZH2 in ovarian cancer", J Cell Mol Med, 24, pp.7479~7489 (2020)
49. Tan X, "LncRNA SNHG1 and RNA binding protein hnRNPL form a complex and coregulate CDH1 to boost the growth and metastasis of prostate cancer", Cell Death Dis, 12, pp.138~ (2021)
50. Yu F, "Loss of lncRNA-SNHG7 promotes the suppression of hepatic stellate cell activation via miR-378a-3p and DVL2", Mol Ther Nucleic Acids, 17, pp.235~244 (2019)
51. Bhan A, "LncRNA HOTAIR : a master regulator of chromatin dynamics and cancer", Biochim Biophys Acta, 1856, pp.151~164 (2015)
52. Yu F, "HOTAIR epigenetically modulates PTEN expression via MicroRNA-29b : a novel mechanism in regulation of liver fibrosis", Mol Ther, 25, pp.205~217 (2017)
53. Amodio N, "MALAT1 : a druggable long non-coding RNA for targeted anti-cancer approaches", J Hematol Oncol, 11, pp.63~ (2018)
54. Miao H, "MALAT1 modulates alternative splicing by cooperating with the splicing factors PTBP1 and PSF", Science Advances, 8, pp.eabq7289~ (2022)
55. Shi C, "lncRNA MALAT1regulates the resistance of breast cancer cells to paclitaxel via the miR-497-5p", SHOC2 axis, 2022, pp.23, 973~985
56. Wang Y, "MALAT1 promotes liver fibrosis by sponging miR‑181a and activating TLR4‑NF‑kappaB signaling", Int J Mol Med, 48, pp.215~ (2021)
57. Prinz F, "The implications of the long non-coding RNA NEAT1 in noncancerous diseases", Int J Mol Sci, 20, pp.627~ (2019)
58. Chakravarty D, "The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer", Nat Commun, 5, pp.5383~ (2014)
59. Li C, "Long noncoding RNA NEAT1 sponges miR-129 to modulate renal fibrosis by regulation of collagen type I", Am J Physiol Renal Physiol, 319, pp.93~105 (2020)
60. Shu B, "METTL3-mediated macrophage exosomal NEAT1 contributes to hepatic fibrosis progression through Sp1", TGFbeta1, Cell Death Discov, pp.2022, 8[DOI]
61. Chen L, "Exosomal miR-103-3p from LPS-activated THP-1 macrophage contributes to the activation of hepatic stellate cells", FASEB J, 34, pp.5178~5192 (2020)
62. Dong Z, "lncRNA GAS5 restrains CCl4-induced hepatic fibrosis by targeting miR-23a through the PTEN", PI3K, Am J Physiol Gastrointest Liver Physiol, pp.2019, 316[DOI]
63. Zhang L, "Long noncoding RNA growth arrest-specific transcript 5 alleviates renal fibrosis in diabetic nephropathy by downregulating matrix metalloproteinase 9 through recruitment of enhancer of zeste homolog 2", FASEB J, 34, pp.2703~2714 (2020)
64. Zhang YY, "LncRNA GAS5 protects against TGF-beta-induced renal fibrosis via the Smad3", miRNA-142-5p axis, 2021, pp.321, 517~526
65. Yu F, "Long non-coding RNA growth arrest-specific transcript 5(GAS5)inhibits liver fibrogenesis through a mechanism of competing endogenous RNA", J Biol Chem, 290, pp.28286~28298 (2015)
66. Luo Y, "Long non-coding RNA GAS5 maintains insulin secretion by regulating multiple miRNAs in INS-1 832", 13 cells, 2020, pp.7, 559267~
67. Qin R, "lncRNA MEG3modulates hepatic stellate cell activation by sponging miR‑145 to regulate PPARgamma", Mol Med Rep, 25, pp.3~ (2022)
68. Li X, "LncRNA ARAP1-AS2promotes high glucose-induced human proximal tubular cell injury via persistent transactivation of the EGFR by interacting with ARAP1", J Cell Mol Med, 24, pp.12994~13009 (2020)
69. Shi S, "Knockdown of LncRNAH19ameliorates kidney fibrosis in diabetic mice by suppressing miR-29a-Mediated EndMT", Front Pharmacol, 11, pp.586895~ (2020)
70. Zhou H, "Paeonol reverses promoting effect of the HOTAIR", miR-124, J Cell Physiol, pp.2019, 234[DOI]
71. Hao J, "Silencing of LncRNA KCNQ1OT1 confers an inhibitory effect on renal fibrosis through repressing miR-124-3p activity", Bioengineered, 13, pp.10399~10411 (2022)
72. Huang H, "lncRNA MALAT1promotes renal fibrosis in diabetic nephropathy by targeting the miR-2355-3p", IL6ST axis, 2021, pp.12, 647650~
73. Wang P, "Long noncoding RNA lnc-TSI inhibits renal fibrogenesis by negatively regulating the TGF-β", Smad3 pathway, 2018, pp.10, eaat2039~
74. Zhu Y, "LncRNA4474 inhibits renal fibrosis by regulating hepatocyte nuclear factor-1beta through miR-615 modulation", Cell Cycle, 21, pp.1233~1248 (2022)
75. Feng Guo, "LncRNA H19 Drives Proliferation of Cardiac Fibroblasts and Collagen Production via Suppression of the miR-29a-3p", miR-29b-3p-VEGFA, Molecules and Cells, pp.2022, 45(3)[DOI]
76. Lu Q, "The lncRNA H19mediates pulmonary fibrosis by regulating the miR-196a", COL1A1 axis, 2018, pp.41, 896~903
77. Yang S, "Long noncoding RNA Kcnq1ot1 prompts lipopolysaccharide-induced acute lung injury by microRNA-7a-5p", Rtn3 axis, 2022, pp.27, 46~
78. Yan W, "MiR-503 modulates epithelial-mesenchymal transition in silica-induced pulmonary fibrosis by targeting PI3K p85 and is sponged by lncRNA MALAT1", Sci Rep, 7, pp.11313~ (2017)
79. Ge Z, "Long noncoding RNA NEAT1 promotes cardiac fibrosis in heart failure through increased recruitment of EZH2 to the Smad7 promoter region", J Transl Med, 20, pp.7~ (2022)
80. Liu Y, "Long non‑coding RNA NEAT1 promotes pulmonary fibrosis by regulating the microRNA‑455‑3p", SMAD3 axis, 2021, pp.23, 218~
81. Tao H, "MeCP2 inactivation of LncRNA GAS5 triggers cardiac fibroblasts activation in cardiac fibrosis", Cell Signal, 74, pp.109705~ (2020)
82. Wang Y, "LncRNA GAS5suppresses TGF-beta1-induced transformation of pulmonary pericytes into myofibroblasts by recruiting KDM5B and promoting H3K4me2", 3 demethylation of the PDGFR alpha, Mol Med, pp.2023, 29[DOI]
83. Ghafouri-Fard S, "Role of miRNA and lncRNAs in organ fibrosis and aging", Biomed Pharmacother, 143, pp.112132~ (2021)
84. Yiu WH, "The long noncoding RNA Meg3 mediates TLR4-induced inflammation in experimental obstructive nephropathy", Clin Sci(Lond), 137, pp.317~331 (2023)
85. Yu F, "LncRNA-MEG3 inhibits activation of hepatic stellate cells through SMO protein and miR-212", Cell Death Dis, 9, pp.1014~ (2018)
86. Yu F, "Correction : LncRNA-MEG3 inhibits activation of hepatic stellate cells through SMO protein and miR-212", Cell Death Dis, 13, pp.133~ (2022)
87. Yu F, "MALAT1 functions as a competing endogenous RNA to mediate Rac1 expression by sequestering miR-101b in liver fibrosis", Cell Cycle, 14, pp.3885~3896 (2015)
88. Shen J, "Recent advances in the role of exosomes in liver fibrosis", J Gastroenterol Hepatol (2023)[DOI]
89. Lou G, "MiR-122 modification enhances the therapeutic efficacy of adipose tissue-derived mesenchymal stem cells against liver fibrosis", J Cell Mol Med, 21, pp.2963~2973 (2017)
90. Rong X, "Human bone marrow mesenchymal stem cells-derived exosomes alleviate liver fibrosis through the Wnt", betacatenin pathway, 2019, pp.10, 98~
91. Nair N, "VP4-and VP7-specific antibodies mediate heterotypic immunity to rotavirus in humans", Sci Transl Med, 9, pp.eaam5434~ (2017)
92. Amodio N, "Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity", Leukemia, 32, pp.1948~1957 (2018)
93. Chen MJ, "Diagnostic value of LncRNA-MEG3 as a serum biomarker in patients with hepatitis B complicated with liver fibrosis", Eur Rev Med Pharmacol Sci, 23, pp.4360~4367 (2019)
94. Xiao Y, "Long Noncoding RNA H19contributes to cholangiocyte proliferation and cholestatic liver fibrosis in biliary atresia", Hepatology, 70, pp.1658~1673 (2019)
95. Zhu Y, "Circulating expression and clinical significance of LncRNA ANRIL in diabetic kidney disease", Mol Biol Rep, 49, pp.10521~10529 (2022)
96. Zhang L, "Altered expression of long noncoding and messenger RNAs in diabetic nephropathy following treatment with rosiglitazone", Biomed Res Int, 2020, pp.1360843~ (2020)
97. Kong C, "Dioscin elevates lncRNA MANTIS in therapeutic angiogenesis for heart diseases", Aging Cell, 20, pp.e13392~ (2021)

관련 논문AI추천